VIA
SRPT icon

Vantage Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Vantage Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25
Closed – – 834
2016
Q2 		$0 Buy
+25
New +$463 ﹤0.01% 896
2016
Q1 		– Sell
-1,000
Closed -$39K – 842
2015
Q4 		$39K Hold
1,000
– – 0.02% 276
2015
Q3 		$32K Hold
1,000
– – 0.02% 286
2015
Q2 		$30K Sell
1,000
-1,000
-50% -$20.4K 0.02% 312
2015
Q1 		$27K Buy
2,000
+1,000
+100% +$13.3K 0.01% 440
2014
Q4 		$14K Hold
1,000
– – 0.01% 447
2014
Q3 		$21K Hold
1,000
– – 0.01% 351
2014
Q2 		$30K Buy
+1,000
New +$31.6K 0.02% 310

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vantage Investment Advisors's SRPT Position: Q3 2016 in Review

Vantage Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 25 shares.

Vantage Investment Advisors first reported a position in SRPT in Q2 2014 and held it in 8 quarters. The position peaked at $39K in Q4 2015. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

  • Vantage Investment Advisors reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Vantage Investment Advisors sold 25 Sarepta Therapeutics shares in Q3 2016.
  • Vantage Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 8 quarters.
  • Vantage Investment Advisors's Sarepta Therapeutics position peaked at $39K in Q4 2015.
  • 186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Vantage Investment Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.